Randomized Multicenter Clinical Trial of the Efficacy of a Telemedicine Monitoring in the Management of a Depressive Episode After an Hospitalisation in Medicine or Surgery
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 836
- 试验地点
- 2
- 主要终点
- Treatment response rate at 6 months after inclusion.
研究概览
简要总结
Major depressive disorder (MDD) is a common chronic disease. It is the main cause of morbidity and disability in the world with, among other things, an increase in cardio-metabolic risk and a reduction in life expectancy, regardless of suicide risk. MDD is the most expensive medical condition: 10-20 billion €/year in France. This cost is mainly attributable to the functional consequences of the disease, highlighting the medico-economic challenge represented by the optimization of the organization of care.
In France, more than 80% of MDD patients are enrolled in non-psychiatric care pathways, mainly primary care or MSO hospital care (medicine, surgery, obstetrics). Unfortunately, less than half of patients benefit from treatment at an appropriate dosage or duration, thus exposing them to the risks of relapse, recurrence and chronic evolution. It is necessary to optimize this management, in particular by improving secondary prevention, which consists of maintaining treatment in the months following symptomatic remission.
Several support programs (monitoring with assessment of symptomatology) have shown their effectiveness on depressive symptomatology with a favorable medico-economic report, in particular by allowing maintenance of antidepressant treatment. None of these studies have been conducted on French care pathways.
Investigators propose to evaluate the efficacy of telemedicine management (added to usual care) in non-psychiatric care pathways on the evolution of depressive symptomatology for MDD patients. Investigators hypothesize that telemedicine monitoring downstream of MSO hospitalization will increase the response rate to antidepressants at 6 months and reduce the costs attributed to depressive symptoms compared to usual care, in particular by optimizing secondary prevention strategies by maintaining treatment.
The main objective of the research is to assess the efficacy of telemedicine monitoring on depressive symptoms and treatments, added to the out-of-hospital downstream care pathways for patients initially hospitalized in MSO (medicine-surgery-obstetrics), compared to usual care.
详细描述
Major depressive disorder (MDD) is a common and often chronic disease. It is the main cause of morbidity and disability in the world with, among other things, an increase in cardio-metabolic risk (diabetes, cardiovascular diseases, high blood pressure) and a reduction in life expectancy, regardless of suicide risk. MDD is the most expensive medical condition: 10-20 billion €/year in France. This cost is mainly attributable to the functional consequences of the disease, highlighting the medico-economic challenge represented by the optimization of the organization of care.
In France, more than 80% of MDD patients are enrolled in non-psychiatric care pathways, mainly primary care or MSO hospital care (medicine, surgery, obstetrics). Unfortunately, less than half of patients benefit from treatment at an appropriate dosage or duration, thus exposing them to the risks of relapse, recurrence and chronic evolution. It is necessary to optimize this management, in particular by improving secondary prevention, which consists of maintaining treatment in the months following symptomatic remission.
Several support programs (monitoring with assessment of symptomatology) have shown their effectiveness on depressive symptomatology with a favorable medico-economic report, in particular by allowing maintenance of antidepressant treatment. None of these studies have been conducted on French care pathways.
Investigators propose to evaluate the efficacy of telemedicine management (added to usual care) in non-psychiatric care pathways on the evolution of depressive symptomatology for MDD patients. Investigators hypothesize that telemedicine monitoring downstream of MSO hospitalization will increase the response rate to antidepressants at 6 months and reduce the costs attributed to depressive symptoms compared to usual care, in particular by optimizing secondary prevention strategies by maintaining treatment.
The main objective of the research is to assess the efficacy of telemedicine monitoring on depressive symptoms and treatments, added to the out-of-hospital downstream care pathways for patients initially hospitalized in MSO (medicine-surgery-obstetrics), compared to usual care.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Presence of DSM5 criteria for the diagnosis of a characterized depressive episode
- •Patient hospitalized in MCO with request for liaison psychiatry opinion whatever the hospitalization modality (full hospitalization, weekday hospitalization or day hospitalization)
- •Initiation, change of molecule or modification of a psychotropic treatment (antidepressant or anxiolytic) during MCO hospitalization by the liaison psychiatrist
- •Affiliated or entitled to a social security system (except AME)
- •Obtaining free, written and informed consent
排除标准
- •Severity of the depressive episode incompatible with outpatient care and relevant to an indication for hospitalization in psychiatry
- •Patient is part of a psychiatric care program at the time of the selection visit
- •Presence of a mood disorder other than CDD
- •Reason for MCO hospitalization secondary to psychiatric disorders, in particular suicide attempts
- •MCO hospitalization prolonged beyond 3 weeks after initiation, change of molecule or modification of psychotropic treatment dosage
- •Psychiatric comorbidities assessed by psychiatrist, in particular addictions (excluding tobacco), delusional disorders, post-traumatic stress disorder, anxiety disorders (excluding GAD)
- •High suicidal risk at the screening visit assessed by psychiatrist
- •Presence of a non-psychiatric condition with a vital prognosis of less than 3 years
- •Contraindications to telemedicine (no internet access, major vision problems, major cognitive problems, marked impulsivity, clinical situation requiring information to be communicated in person, etc.)
- •Conditions making consent impossible (major cognitive disorders, etc.)
- •Deprived of liberty or under a protective measure (guardianship or under curatorship)
- •Pregnant woman
- •Refusal of the patient
结局指标
主要结局
Treatment response rate at 6 months after inclusion.
时间窗: At 6 months
The response to treatment is defined by a decrease of at least 50% in the Hospital Anxiety and Depression Scale (HADS-Depression) score compared to the baseline. The scale contains 14 items and consists of two subscales: anxiety and depression. Each item is rated on a four-point scale. For the depression score, the minimum value is 0 and the maximum value is 21 in such a way that higher scores mean higher depressive symptoms intensity.
次要结局
- Quality of life score(At inclusion, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months)
- Measurement of stigma scale scores and subscores in each group(At inclusion and 6 months)
- Evaluation of the possibility of the physicians to require a psychiatric opinion on the care(At inclusion, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months)
- Identification of the use of NICT tools (New Information and Communication technologies)(At inclusion, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months)
- Number of relapse episodes for the improvement of secondary prevention objective(At inclusion, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months)
- Therapeutic efficacy(At 36 months)
- Evaluation of the satisfaction of depression care(At inclusion, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months)
- Incremental cost-utility ratio over the 3 years of follow-up(A inclusion, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months)
- Frequency of the use of NICT tools (New Information and Communication technologies)(At inclusion, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months)
- Medication compliance and integration into a psychiatric care pathway(At inclusion, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months)
- Evaluation of the feasibility and satisfaction of telemedicine tools by patients included in the experimental group(At inclusion, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months)
- Clinical variables associated with drop out of the care program(At inclusion, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months)